Saltar al contenido
MilliporeSigma
Todas las fotos(1)

Documentos

Y0001380

Olanzapine for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Olanzapine, 2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C17H20N4S
Número de CAS:
132539-06-1
Peso molecular:
312.43
Beilstein/REAXYS Number:
7655141
MDL number:
MFCD00866702
UNSPSC Code:
41116107
PubChem Substance ID:
329831393
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

olanzapine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CN1CCN(CC1)C2=Nc3ccccc3Nc4sc(C)cc24

InChI

1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

InChI key

KVWDHTXUZHCGIO-UHFFFAOYSA-N

Gene Information

human ... DRD2(1813) , DRD3(1814) , DRD4(1815) , HTR2A(3356) , HTR2C(3358)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Olanzapine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbones
GHS06

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Central nervous system

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

Choose from one of the most recent versions:

Certificados de análisis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Jacqueline Flank et al.
Pediatric blood & cancer, 62(3), 496-501 (2014-10-21)
This retrospective review provides preliminary data regarding the safety and efficacy of olanzapine for chemotherapy-induced vomiting (CIV) control in children. Children <18 years old who received olanzapine for acute chemotherapy-induced nausea and vomiting (CINV) control from December 2010 to August
Hirotake Hida et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(3), 601-613 (2014-08-15)
Blonanserin differs from currently used serotonin 5-HT₂A/dopamine-D₂ receptor antagonists in that it exhibits higher affinity for dopamine-D₂/₃ receptors than for serotonin 5-HT₂A receptors. We investigated the involvement of dopamine-D₃ receptors in the effects of blonanserin on cognitive impairment in an
Susan L McElroy et al.
Current psychiatry reports, 17(5), 35-35 (2015-03-23)
Psychopharmacologic treatment is playing a greater role in the management of patients with eating disorders. In this paper, we review randomized, placebo-controlled trials (RCTs) conducted in anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), and other eating disorders
Erin Schwenger et al.
Clinical pharmacokinetics, 50(7), 415-428 (2011-06-10)
Olanzapine, a second-generation antipsychotic, is a first-line agent in the treatment of schizophrenia. The objective of this review was to determine whether olanzapine warrants clinical pharmacokinetic monitoring in patients with schizophrenia, using a previously published decision-making algorithm. Although olanzapine is
Frantiescoli A Dimer et al.
Journal of biomedical nanotechnology, 10(6), 1137-1145 (2014-04-23)
Olanzapine is an atypical antipsychotic drug, whose chronic use has been associated with the development of potential adverse effects such as weight gain and cardio-metabolic disorders like hypercholesterolemia and diabetes. To circumvent these side effects, the controlled release of olanzapine
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico